drugset / Trial / NCT05649956
Letrozole in Uterine Leiomyosarcoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.
Timeline
- Start
- 2024-07-17
- Primary completion
- 2028-07-30
- Completion
- 2029-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |